The Perspective of the Intensivist on Inotropes and Postoperative Care Following Pediatric Heart Surgery: An International Survey and Systematic Review of the Literature by Roeleveld, N. (Nel) & de Klerk, J.C.A. (Johan C. A.)
Original Article
The Perspective of the Intensivist on
Inotropes and Postoperative Care
Following Pediatric Heart Surgery:
An International Survey and Systematic
Review of the Literature
Peter P. Roeleveld, MD1 , and J. C. A. de Klerk, MD2
Abstract
Introduction: Inotropes are frequently being used in children undergoing heart surgery to prevent or treat low cardiac output
syndrome (LCOS). There is only limited evidence that inotropes actually positively influence postoperative outcome. Our aim
was to describe the current international practice variation in the use of inotropes following congenital heart surgery.Methods:
We developed an online survey regarding the postoperative use of inotropes. We sent an invitation to all 197 registered
members of the Pediatric Cardiac Intensive Care Society (PCICS) to participate in the survey. We also performed a systematic
review of the literature. Results: Ninety-eight people (50%) responded, representing 62 international centers. Milrinone is
routinely used perioperatively by 90 respondents (97%). Adrenaline/epinephrine is routinely used by 43%, dopamine by 36%,
dobutamine by 11%, and levosimendan by 6%. Steroids are used routinely by 54% before initiating cardiopulmonary bypass.
Vasopressin is used by 44% of respondents. The development of LCOS is monitored with lactate in 99% of respondents, physical
examination (98%), intermittent mixed venous saturation (76%), continuous mixed venous saturation (13%), echocardiography
(53%), core–peripheral temperature gap (29%), near-infrared spectrometry (25%), and 4% use cardiac output monitors (PiCCO,
USCOM). To improve cardiac output, 42% add/increase milrinone, 37% add adrenaline, and 15% add dopamine. Rescue therapy is
titrated individually, based on the patients’ pathophysiology. A systematic review of the literature failed to show compelling
evidence with regard to the benefit of inotropes. Conclusions: Despite the lack of sufficient evidence, milrinone is used by the
vast majority of caregivers following congenital heart surgery.
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Introduction
Inotropes are frequently being used in children undergoing
heart surgery to prevent or treat low cardiac output syndrome
(LCOS) that typically occurs 6 to 18 hours after cardiopulmon-
ary bypass (CPB) surgery.1 There is ample evidence describing
how certain inotropes affect the hemodynamics in adults and
children undergoing heart surgery. But there is only limited
evidence that certain inotropes actually positively influence
postoperative outcome.2 A recent Cochrane review concluded
there is insufficient evidence of effectiveness of prophylactic
milrinone in preventing death or LCOS in children under-
going surgery for congenital heart disease, compared to pla-
cebo.3 There is no evidence in the literature in favor of one
inotrope over another in improving postoperative outcomes.
The aim of this study was to describe current international
practice variation regarding the use of inotropes in children
undergoing heart surgery.
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Abbreviations and Acronyms
ACE angiotensin converting enzyme
cAMP cyclic adenosine monophosphate
CPB cardiopulmonary bypass
DHCA deep hypothermic circulatory arrest
ECMO extracorporeal membrane oxygenation
iNO inhaled nitric oxide
LCOS low cardiac output syndrome
LOS length of stay
MAP mean arterial blood pressure
MV mechanical ventilation
NIRS near-infrared spectrometry
PAP pulmonary artery pressure
PCICS Pediatric Cardiac Intensive Care Society
PICU pediatric intensive care unit
PVR pulmonary vascular resistance
SVR systemic vascular resistance
PICCO pulse index continuous cardiac output
USCOM Doppler cardiac output measurement
Methods
Survey
In May 2014, we developed an online survey for the members
of the Pediatric Cardiac Intensive Care Society (PCICS), with
questions regarding the prevention and treatment of LCOS in
pediatric patients after cardiac surgery.
The questionnaire consisted of 22 questions covering differ-
ent aspects of postoperative management in children who
underwent cardiac surgery. Most of the questions concerned
the treatment and prevention of LCOS in children while other
questions where about postoperative temperature control. The
management of hypertension in patients who underwent sur-
gery for coarctation of the aortae was part of the same survey
and published separately.4 Most questions could be answered
with multiple answers. Respondents were free not to answer a
question if they chose not to do so, therefore not all questions
were answered by all 98 respondents.
Survey Participants
We sent an invitation to partake in the survey to all 197 regis-
tered PCICS members at the time. In the accompanying letter it
was mentioned that all responses would be analyzed anon-
ymously and that it was the intention to publish the results. A
reminder was sent after two and four weeks if they had not yet
responded. Data were collected between May and June 2014.
Data Analysis
The results are descriptive and were expressed as percentages.
No comparative statistical tests were performed.
Literature Review
The authors searched PubMed for all known inotropes and
cross-referenced them with key words such as “pediatric,”
“child,” “neonate,” “newborn,” “cardiac,” “heart,”
“congenital,” and “surgery.” The authors also scanned all
references in the found articles and then read all titles and
abstracts of relevant studies. Then randomized controlled
trials were selected in which inotropes were compared
with each other or with placebo in pediatric or congenital
cardiac surgery, or animal models of congenital heart
surgery.
Results
Survey Participants
Ninety-eight people (50%) responded from 62 different medi-
cal centers across the world (center distribution: 61% United
States, 15% Europe, 8% Canada, 6% Asia, 3% Australia, 3%
South America, and 2% Africa; see Table 1). Fifty-six (73%)
respondents were pediatric intensive care unit (PICU) consul-
tants, 27 (35%) pediatric cardiologists, 23 (23%) nurse practi-
tioners, 3 (3%) cardiothoracic surgeons (3%), 5 (5%)
anesthesiologists, and 4 (4%) PICU trainees. Several medical
respondents were dually certified (PICU and cardiology). Most
respondents (63%) worked in centers with more than 300
pediatric heart surgeries per year.
Table 1. Demographics of the Respondents: Origin, Specialization,
and Number of Operations Performed at Their Center per
Annum.a,b,c
Individual distribution N %
United States 65 66
Europe 10 10
Canada 8 8
Australia 5 5
Asia 4 4
South America 5 5
South Africa 1 1
Total 98 100
Center distribution
United States 38 61
Europe 9 15
Canada 5 8
Australia 3 3
Asia 4 6
South America 2 3
South Africa 1 2
Total 62 100
Center size (operations per annum)
Less than 100 5 5
100-200 9 9
200-300 22 22
300-400 24 25
400-500 16 16
More than 500 22 22
Abbreviation: PICU: pediatric intensive care unit.
aEurope: France, Germany, Italy, the Netherlands, Poland, Sweden, United
Kingdom.
bAsia: India, Israel, United Arab Emirates.
cSouth America: Argentina, Colombia.
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Drug Choice for the Prevention of LCOS
Ninety-three (95%) of all 98 respondents answered this ques-
tion. The prevention of LCOS is characterized by considerable
variability (see Table 2). Eight different drugs used for the
prevention of LCOS. Most respondents use milrinone (97%)
routinely for the prevention of LCOS. Other frequently used
drugs for the prevention of LCOS are adrenaline (45%) and
dopamine (38%). Dobutamine is used by 11% and levosimen-
dan by 5% of respondents.
There is marked variability in the timing of initiating pro-
phylactic inotropes. Respondents could give multiple answers
as individual clinical indication might necessitate different tim-
ing. Forty-two percent start the inotrope at the start of CPB,
63% indicate starting while coming off CPB, and 29% started
inotropes when the patient arrives in the ICU.
Sixty-nine respondents (70%) indicated that they routinely
use other pharmacological agents besides their main inotrope.
Other medications that are frequently used concomitantly are
noradrenaline/norepinephrine (55%), steroids (54%), and vaso-
pressin (43%). Thirty percent of respondents indicate that they
give noradrenaline/norepinephrine routinely to maintain blood
pressure while giving milrinone. Vasodilators such as
angiotensin-converting-enzyme (ACE) inhibitors and alpha-
agonists are routinely used by 10 (15%) of 69 and 7 (10%) of
69, respectively. Adrenaline/epinephrine is routinely used by 3
(4%) of 69 of respondents.
Out of 69 who answered this question, 57 (83%) respondents
specifically indicated that the use of these second-tier medica-
tions is based on clinical requirements. The strategies used vary
from the use of vasopressors in vasodilated states to improve
perfusion pressures, to vasodilators in order to promote after-
load reduction and cardiac output.
When steroids are used, they are mostly given before going
on CPB (54%) and in 15% it is routinely continued after the
bypass.
Monitoring Cardiac Output
Ninety-one respondents indicated the use of different methods
to monitor cardiac output postoperatively (see Table 3). Lactate
(99%), physical examination (98%), and intermittent or con-
tinuous venous saturation (89%) are mostly used for monitor-
ing cardiac output. Echocardiography is used by 53% of the
respondents, core–peripheral temperature gap by 32%, and
near-infrared spectrometry (NIRS) is used by 26%. The use
of minimally invasive cardiac output monitoring (e.g. pulse
index continuous cardiac output [PICCO, Pulsion, Germany]
or Doppler hemodynamic cardiac output monitoring [USCOM
Ltd, Australia] is limited (3%).
Drug Choice for Improving Cardiac Output
Most respondents indicate that their choice of drugs for
improving cardiac output is based on the pathophysiology of
the underlying condition, the severity of the LCOS, and the
medication that is already being administered. Eighty-five
respondents (85/98 ¼ 87%) answered this question and indi-
cated increasing either milrinone (42%) or adrenaline/epi-
nephrine (36%) when cardiac output is worsening (see Table
4). If this treatment fails, then in most of the cases adrenaline/
epinephrine (40%) will be added as the second drug of choice.
Under “other” 17% indicated that clinical circumstances
Table 2. Reports of Drugs Regimen for Prevention of LCOS and
Timing of Administration.a
Prophylactic drug regimen N %
Milrinone 90/93 97
Adrenaline/epinephrine 42/93 45
Dopamine 35/93 38
Dobutamine 10/93 11
Levosimendan 5/93 5
Other 10/93 11
Not answered 5/98 5
Timing of administration
Preoperatively 1/93 1
After anesthetic induction 1/93 1
When on CPB 39/93 42
While coming off CPB 59/93 63
In PICU 27/93 29
Other 5/93 5
Not answered 5/98 5
Other drugs used
Noradrenaline/norepinephrine 38/69 55
Alpha blockers 7/69 10
ACE-inhibitors 10/69 15
Steroids (before CPB) 37/69 54
Steroids continued after CPB 10/69 15
Vasopressin 30/69 43
Adrenaline/epinephrine 3/69 4
Other (triiodothyronin, calcium, epinephrine) 15/69 22
Not answered 29/98 30
Abbreviations: ACE, angiotensin converting enzyme; CPB, cardiopulmonary
bypass; LCOS, low cardiac output syndrome; PICU, pediatric intensive care
unit.
aMultiple answers possible.
Table 3. Monitoring of Development of LCOS. Multiple Answers
Possible. NIRS: Near-infrared Spectrometry.
Monitoring modality N %
Lactate 90/91 99
Physical examination 89/91 98
Intermittent venous saturation 69/91 76
Echocardiography 48/91 53
Core–peripheral temperature gap 26/91 32
NIRS 24/91 26
Continuous venous saturation 12/91 13
PICCO 2/91 2
USCOM 1/91 1
Other 4/91 4
Not answered 7/98 7
Abbreviations: LCOS, low cardiac output syndrome; NIRS, near-infrared
spectrometry; PICCO, pulse index continuous cardiac output; USCOM,
Doppler cardiac output measurement.
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directed their specific therapies. Extracorporeal membrane
oxygenation (ECMO) was also given as an option several times
but was not specified by many other respondents. The timing of
initiating ECMO postcardiotomy remains challenging. It was
not a part of this survey.
Managing Cardiac Output in a Mixed Circulation
Eighty-nine respondents (91%) answered questions regarding
specific management in mixed circulations (see Table 5). In a
mixed circulation, the majority will try to decrease the systemic
vascular resistance (SVR) to promote systemic circulation
(79%). Forty-two percent will try to increase pulmonary vas-
cular resistance (PVR) to promote systemic cardiac output. A
combination of both is indicated by 17%, which is probably an
underestimation because we did not specifically ask how many
used a combination.
To achieve an increase in PVR, respondents will try to
achieve hypoventilation (61%), increase hemoglobin (46%),
lower inhaled oxygen concentration below 21% (45%), and/
or increase positive end expiratory pressure (36%). All 85
respondents of this question indicate the use of a combination
of these nonpharmacological strategies.
Eighty-eight respondents answered the question regarding
decreasing SVR. Almost all (87/88) aim to lower SVR by using
milrinone (99%) followed by nitroprusside (53%), ACE-
inhibitors (26%), alpha-blockers (17%), nitroglycerin (8%),
or others like nicardipine or phenoxybenzamine (8%).
Temperature Regulation in PICU
Eighty-seven (89%) and 81 (83%) of 98 respondents answered
the questions about temperature management post CPB and
post deep hypothermic circulatory arrest (DHCA) respectively
(see Table 6). Postoperative hyperthermia is prevented routi-
nely in PICU in the majority of the respondents following CPB
(52%) with or without DHCA (48%). Only about 8% will rou-
tinely try to achieve mild hypothermia (35C-36C or 95F-
97F). Nine respondents (10%) indicate that hypothermia will
be used in patients for heart rate control (eg, in case of junc-
tional ectopic tachycardia).
Systematic Review of the Literature
We identified 20 randomized controlled trials comparing ino-
tropes in (animal models of) congenital pediatric heart surgery.
Table 7 gives a clear overview of these studies, including
design, subjects, the presented results, and the effects on clini-
cally relevant outcomes such as mortality, duration of mechan-
ical ventilation (MV), and length of stay (LOS). Of those 20
studies, 2 were crossover studies reporting on hemodynamic
variables5,7 and 2 were animal studies.11,12 Of the remaining 16
studies in children, 6 studies reported on mortality.2,14,17,18,20,21
In none of these studies, mortality was positively (or nega-
tively) influenced by the studied inotrope. Duration of MV or
LOS (PICU and/or hospital) was reported by 10 of the 16
studies.2,13,14,16-18,20-23 Only in one report the duration of MV
was positively influenced, by a combination of milrinone and
inhaled nitric oxide (iNO) in children following the Fontan
operation.21 In the other nine studies, no positive effect of
Table 5. Strategy in Patients With Mixed Circulation.a
N %
Routinely decrease SVR, with 70/89 79
Milrinone 87/88 99
Nitroprusside 47/88 53
Nitroglycerin 7/88 8
Alpha-blockers 15/88 17
ACE-inhibitors 23/88 26
Others 7/88 8
Routinely increase PVR, with 37/89 42
Increasing PEEP 31/85 36
Lowering FIO2 < 21% 38/85 45
Hypoventilation 52/85 61
Increase hemoglobin/hematocrit 39/85 46
Do not increase PVR but lower SVR 12/85 14
Abbreviations: ACE, angiotensin converting enzyme; SVR: systemic vascular
resistance; PVR, pulmonary vascular resistance; PEEP, positive end expiratory
pressure.
aMultiple answers possible.
Table 4. Reports of Drugs Regimen for Treatment of LCOS.a
First Choice Second Choice
N % N %
Milrinone 36/85 42 13/86 15
Dobutamine 2/85 2 1/86 1
Dopamine 13/85 15 8/86 9
Adrenaline/epinephrine 31/85 36 34/86 40
Noradrenaline/norepinephrine 0/85 0 0/86 0
Levosimendan 1/85 1 3/86 3
Steroids 2/85 2 9/86 10
Vasodilators 0/85 0 4/86 5
Others (eg, ECMO) 17/98 17 14/86 16
Not answered 13/98 13 12/98 12
Abbreviations: ECMO, extracorporeal membrane oxygenation; LCOS, low
cardiac output syndrome.
aOne answer only.
Table 6. Temperature Management Following Pediatric Heart
Surgery.
After CPB After CPB with DHCA
N % N %
No temperature protocol 13/87 15 19/81 23
Prevent hyperthermia >38C 45/87 52 39/81 48
36C-37C 22/87 25 16/81 20
35C-36C 7/87 8 7/81 9
Abbreviations: CPB, cardiopulmonary bypass; DHCA, deep hypothermic
circulatory arrest.
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Table 7. All Published Randomized Controlled Trials of Inotropes in (Models of) Pediatric Cardiac Surgery.a
Author, Year
of Publication Inotropes Subjects Results
Effect on
Mortality?
Effect on Mechanical
Ventilation or LOS?
Booker et al
1995.5
Dopamine vs
Dobutamine.
Crossover
study
19 children undergoing
cardiac surgery
No significant hemodynamic
differences
NA NA
Wenstone,
et al 19916
Dobutamine vs
dopamine.
142 children undergoing
CPB surgery.
No difference in renal function or
urine output
Not available Not available
Kwapisz, et al
20097
Dobutamine vs
Dopexamine.
Crossover
design
11 children undergoing
cardiac surgery
Both drugs similarly increased
cardiac index (measured via
transpulmonary thermodilution)
NA NA
Jaccard et al
19848
Dobutamine vs
Isoprenaline.
12 children after
correction of
Tetralogy of Fallot
Isporenaline was more effective than
Dobutamine in raising CI.
Not available Not available
Bailey et al
19979
Amrinone vs
sodium
nitroprusside
(SNP).
Crossover
study.
10 infants after cardiac
surgery
Amrinone resulted in significant
increase in cardiac index. (SNP did
not)
NA NA
Innes et al
1994.10
Dobutamine vs
Enoximone.
28 children following
cardiac surgery
Mean arterial pressure significantly
higher in Dobutamine group. No
difference in CI
Not available Not available
Stocker et al
200711
Milrinone vs
levosimendan
vs placebo
Animal model of
pediatric CPB. 16
piglets.
Placebo decreased CO by 15%.
Milrinone maintained CO.
Levosimendan increased CO 14%
Not available Not available
Riordan et al
199612
Dobutamine vs
Adrenaline vs
Dopamine
Animal model of HLHS.
n¼6
All three drugs increased CO. Only
adrenaline significantly decreased
Qp/Qs and increased systemic
oxygen delivery.
NA NA
Hoffman et al
20032
Milrinone vs
placebo
(PRIMACORP)
238 children after
cardiac surgery
High-dose milrinone (0.75 mg/kg/min)
reduced the relative risk of LCOS
by 55% (P¼ .023). No difference in
urine output, creatinine clearance,
lactate, or mixed venous
saturation.
No difference in
mortality
No difference in
duration of MV or
LOS.
Laitinen et al
199713
Amrinone vs
dopamine &
nitroglycerin
32 infants after AVSD
repair
Systemic and pulmonary blood flow
were higher in Amrinone group
with lower oxygen consumption
No mortality No difference in
duration of MV or
LOS
Laitinen et al
199914
Amrinone vs
dopamine &
nitroglycerin.
35 Neonates after
arterial switch
operation
Amrinone provided better CO,
lower SVR, and lower oxygen
consumption
Not available No difference in
duration of MV, or
LOS
Momeni et al
201115
Levosimendan vs
Milrinone.
36 children after
congenital heart
surgery
No difference in lactate 4 hours
postop. Less oxygen demand with
levosimendan
Not available Not available
Lechner et al
201216
Levosimendan
(0.1) vs
Milrinone (0.5).
40 infants after
corrective open heart
surgery
Postoperative CO similar
(transesophageal Doppler). HR,
systemic arterial pressure, LAP,
MvsO2, lactate, fractional
shortening and NIRS were all
similar.
Not available No difference in
duration of MV or
LOS
Ebade et al
201317
Levosimendan vs
Dobutamine.
50 children with
pulmonary
hypertension
undergoing surgical
repair of cardiac
septal defects
Both significantly decreased PAP and
CI. But levosimendan was more
potent
No mortality No difference in
duration of MV or
ICU LOS
(continued)
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inotropes was found on important outcome measures such as
duration of MV and LOS.
Discussion
This is the first international survey of the use of inotropes and
intensive care management after pediatric cardiac surgery.
There have been one Italian and one European survey concern-
ing pediatric LCOS.24-26
Prevention of Low Cardiac Output Syndrome
The results of this survey show that, worldwide, milrinone is
being used by 97% of respondents for the prevention of LCOS
in children (Table 2). The other drugs used are adrenaline/
epinephrine (45%), dopamine (38%), dobutamine (11%), and/
or levosimendan (5%). These results include the use of multiple
drugs. This diversity in pharmacological approaches reflects
the current lack of sufficient guiding evidence in the literature.3
In 2011, a European survey also reported a marked varia-
bility with milrinone as the most used inotrope (71%) in pedia-
tric cardiac surgery patients which is significantly fewer than
97% in our survey.24 In their survey, dopamine (19%) and
adrenaline (16%) were used much less frequently than in our
survey (45% and 38%, respectively). A recent single-country
survey reported that a combination of dopamine and milrinone
was the most frequent drug regimen for prevention of LCOS
after congenital heart surgery in Italy.26 This difference in the
use of inotropes could reflect differences in European and
American approach to the use of inotropes as most of our
respondents were North American or Canadian. Due to the
design of our study and the survey engine used, it was not
possible to do a subanalysis and compare continents.
Improving Cardiac Output
To improve postoperative cardiac output, there is more diver-
sity in inotrope use, whereby milrinone, adrenaline/epinephr-
ine, dopamine, and dobutamine are mostly used (Table 4). In
the European and Italian surveys, milrinone was most often
used for the treatment of LCOS with elevated SVR or elevated
PVR.25,26 In the European study, dobutamine is preferred for
the treatment of LCOS with low SVR, but adrenaline/epinephr-
ine or dopamine were first and second choice in the Italian
survey. In this current survey, the authors did not specify the
different kinds of LCOS (high SVR, low SVR).
Table 7. (continued)
Author, Year
of Publication Inotropes Subjects Results
Effect on
Mortality?
Effect on Mechanical
Ventilation or LOS?
Ricci et al
201218
Levosimendan &
Milrinone &
dopamine vs
Milrinone &
dopamine.
63 newborns after
cardiac surgery
LCOS in 37% of levosimendan
patients and in 61% of standard
regimen (P ¼ .059). Lower lactate,
heart rate, and inotrope score in
levosimendan group.
No
improvement
in mortality
No improvement in
duration of MV or
LOS
Pellicer et al
201319
Levosimendan vs
Milrinone.
20 children undergoing
cardiovascular
surgery
Infants receiving Levosimendan had
higher peripheral oxygenation
(NIRS) and lower inotrope scores.
No differences in pro-BNP,
troponin, or echo findings.
Not available Not available
Costello et al
201420
Nesiritide vs
Milrinone vs
Placebo.
106 children after
Fontan surgery
No difference in median days alive.
No difference in cardiac index,
inotropes scores
No difference No difference in
duration of MV or
LOS
Cai et al
200821
Nitric oxide vs
Milrinone vs
nitric oxide &
Milrinone
64 children with high
PVR following Fontan
surgery
Combination of nitric oxide &
Milrinone led to most significant
reduction in PVR and
improvement of oxygenation. All
three combinations significantly
improved systemic circulation.
No mortality Time on MV was
shortest in
combined iNO and
milrinone group. No
difference in LOS.
Bettendorf
et al. 200022
Triiodothyronine
vs placebo
40 children after cardiac
surgery
CI and systolic function improved
significantly
Not available No significant
difference in
duration of MV or
LOS
Chowdhury
et al 200123
Triiodothyronine
vs placebo
75 children after cardiac
surgery
No difference in outcome measures.
Significantly lower inotrope score
only in newborn subgroup
Not available No effect on LOS or
duration of MV
Abbreviations: NA, not applicable (because of the design of some trials mortality could not be studied); MV, mechanical ventilation; LOS, length of stay; Vs, versus;
CO, cardiac output; CI, cardiac index; iNO, inhaled nitric oxide; LCOS, low cardiac output syndrome; PVR, pulmonary vascular resistance; NIRS, near-infrared
spectrometry; SVR, systemic vascular resistance; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; Qp/Qs, pulmonary to systemic
blood flow ratio; CPB, cardiopulmonary bypass; HLHS, hypoplastic left heart syndrome.
aAll are randomized controlled trials unless otherwise mentioned.
Roeleveld and Klerk 15
Thus, in this and other surveys, multiple drugs are used for
the prevention and treatment of LCOS in pediatric patients
after cardiac surgery. But there seems to be a clear preference
for milrinone despite the lack of compelling evidence for its
benefit over other drug regimens.3
The Ideal Inotrope
The ideal inotrope would consistently improve systolic and
diastolic cardiac function, decrease afterload, improve cardiac
output, have a favorable effect on myocardial oxygen hemody-
namics, and improve survival and quality of life, with as little
adverse effects and interactions as possible. Furthermore, ide-
ally, different specific inotropes would have proven effects and
benefits for specific disease states. Unfortunately, the ideal
inotrope does not exist. But the (cardiac) intensivist does have
a number of pharmacological options at his or her disposal with
well-known hemodynamic effects.27
Milrinone. Multiple studies in adults, and children, have shown
the positive hemodynamic effects in response to milrinone, an
effect not seen in preterm infants.28-34 Milrinone is a phospho-
diesterase inhibitor and improves contractility by inhibiting the
breakdownof cyclic adenosinemonophosphate (cAMP).29Other
effects are afterload reduction and improved diastolic function
(lusotropy) with minimal increase in myocardial oxygen con-
sumption. Together these effects lead to an increased cardiac
index and decrease in the mean arterial blood pressure (MAP).
Milrinone has a relatively long half-life of 2 to 4 hours.35,36
Stocker et al showed that milrinone can maintain normal cardiac
output in an animal model of congenital heart surgery.11
Milrinone in the pediatric population was first described in
1995 by Chang et al in ten neonates following cardiac sur-
gery.37 The authors, using a thermodilution pulmonary artery
catheter (Baxter Edwards Critical-Care, Irvine, CA), measured
an increase in cardiac index from 2.1 (+ 0.5) to 3.0 (+ 0.8)
L/m2/min with the use of 0.5 mg/kg/min milrinone and 3 to
7 mg/kg/min dopamine, without increased myocardial oxygen
consumption. This was not a controlled trial and they did not
comment on clinical outcomes. Then in 1998, a pharmacoki-
netic study in 19 infants and children reported therapeutic
plasma levels with both 0.5 and 0.75 mg/kg/min milrinone with
reduced clearance compared to adults, especially in infants.38
They also did not report on clinical outcomes.
In the landmark Primacorp study, by Hoffman et al, a high-
dose milrinone (0.75 mg/kg/min) led to a significant reduction
in surrogate markers of low cardiac output by 55% in children
after biventricular repair.2 However, there was no difference in
lactate, duration of MV, hospital LOS, or mortality. Low-dose
milrinone (0.25 mg/kg/min) showed no benefit compared to
placebo. Unfortunately the dose of milrinone used was not
addressed in the current survey. It might be that underdosing
of milirinone can explain the lack of positive effects on clini-
cally relevant outcomes.39
A pharmacological study in 2013 showed that a median dose
of milrinone of 0.5 mg/kg/min led to either sub- or
supratherapeutic levels (<100 and >300 ng/mL, respectively)
in 52% of the patients.40 The authors report that there is an
association between LCOS (defined as lactate > 2 mmol/L) and
supratherapeutic milrinone blood levels, there was no associa-
tion between subtherapeutic blood levels and LCOS. There was
a higher incidence of arrhythmias with milrinone levels
>200 ng/mL, but otherwise no correlation was found between
blood levels and clinical outcomes such as hypotension,
tachycardia, or lactate. However, milrinone dosing was not
protocolized and given at the discretion of the treating physi-
cian, which may have confounded the results. The authors
report an important suboptimal use of milrinone but do not
comment on clinical outcome measures such as duration of
MV, hospital LOS, and/or mortality.40
A pharmacokinetic drug-disease model, reported by Vogt
et al, also suggests that the current dosage for prevention as well
as for treatment of LCOS might not be sufficient and suggests
dosing should be age stratified.39 Another pharmacological
study conversely suggested the use of lower dose milrinone
(0.2 mg/kg/min) because of drug accumulation post CPB surgery
in children.41 The effects of these age-related doses on the car-
diac output and clinical outcomes remain to be investigated.
The only study in which milrinone improved an important
clinical outcome was reported by Cai et al who showed that in
46 children following Fontan-type surgery, combined use of
iNO and milrinone (0.5 mg/kg/min) did significantly reduce the
duration of MV.21 Length of hospital stay, however, was not
affected.
In adults there have been concerns of chronic use of milri-
none increasing mortality.42,43 However, a more recent meta-
analysis of 20 randomized trials showed no increased mortality
due to milrinone in adult patients undergoing cardiac surgery.44
But the higher-quality trials did suggest a trend toward
increased mortality with milrinone. Although pediatric studies
were included, no pediatric subanalysis was performed. Adults
with chronic heart failure are very different than young chil-
dren with congenital heart defects following surgery, but
unlimited use of milrinone might not be without harm.
Therefore, we can conclude from the literature that there is
insufficient evidence that milrinone improves clinical out-
comes post pediatric heart surgery, a finding confirmed by a
recent Cochrane review.3
However, despite this lack of evidence, the positive hemody-
namic effects of milrinone do lead to a widespread use as shown
in our and other surveys.24-26 One of the hemodynamic effects is
vasodilation with afterload reduction leading to improved car-
diac output, however, there is also a high concomitant use of
vasopressors as 55% report the use of noradrenaline and 43% use
vasopressin to treat low SVR and blood pressure in our survey.
Therefore, we must ask ourselves how much of the beneficial
effect of milrinone is being counteracted by the use of vasopres-
sors. This may be a reason why no study has yet been able to
report a positive effect on clinical outcomes.
Adrenaline/Epinephrine. Epinephrine or adrenaline, is an endo-
genous catecholamine with dose-dependent effects. At lower
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doses (0.05-0.1 mg/kg/min), it stimulates the beta-adrenergic
receptors leading to increased contractility, increased heart
rate, and afterload reduction through peripheral vasodila-
tion.45,46 At higher doses (>0.1 mg/kg/min), it also stimulates
alpha-adrenergic receptors leading to vasoconstriction. The sti-
mulation of the beta-receptors leads to an increased calcium
influx into the myocardial cell and increased cAMP, at the cost
of increased oxygen consumption. In 1979, Benzing et al
reported that the cardiac index in 13 children after cardiac
surgery increased significantly when epinephrine was added
to sodium nitroprusside, without a significant change in sys-
temic resistance.47
In animal models of single ventricle physiology, adrenaline
increased cardiac output, systemic perfusion, and systemic
oxygen delivery.12,48 Despite the fact that there are no rando-
mized controlled trials with adrenaline in pediatric heart sur-
gery, 45% and 40% of respondents use adrenaline for
prevention and treatment of LCOS, respectively, in this survey.
Dobutamine. Dobutamine is a synthetic catecholamine, with a
short half-life of two minutes, which asserts its effect through
beta receptors, stimulating a calcium influx and increase in
cAMP. It has positive inotropic and chronotropic effects with
peripheral systemic vasodilatation and no pulmonary vasodila-
tation.8,49-52 Important side effects are arrhythmias and
increased myocardial oxygen consumption. Several adult and
pediatric studies have found that dobutamine led to an increase
in cardiac index in patients who underwent cardiac surgery, due
to an increase in heart rate without an increase in stroke vol-
ume.8,34,49 Myocardial oxygen uptake and coronary blood flow
is increased with dobutamine.53 In an animal model, Ferrara
has found that dobutamine at higher dosage produced an
increase in cardiac output only in term animals compared to
preterm animals, with a significant increase in mean systemic
arterial blood pressure.54 When compared to enoximone, dobu-
tamine also increased the MAP, but there was no difference in
cardiac output in a study of 28 children following heart sur-
gery.10 The authors did not comment on mortality, duration of
MV, or LOS. There is, to our knowledge, no literature on the
effect of dobutamine on clinically relevant outcomes in chil-
dren after heart surgery despite its well-known hemodynamic
effects. Dobutamine to prevent LCOS is used routinely by 11%
in this survey.
Dopamine. Dopamine also has dose-dependent actions but with
relatively unpredictable dose response.5,55 In low doses
(<5 mg/kg/min) dopamine acts on dopaminergic receptors indu-
cing natriuresis, diuresis, and increased mesenteric flow.54,56 In
medium dose (5-15 mg/kg/min) dopamine stimulates beta1-
adrenergic receptors increasing cardiac output through chron-
otropy (mild effect), inotropy, and afterload reduction and
increases glomerular filtration rate (GFR) and urine
output through via dopaminergic receptors.57 At high doses
(>15 mg/kg/min) peripheral resistance increased via alpha-
receptors leading to an increased MAP. Side effects are
increased myocardial oxygen consumption, arrhythmias,
hypothyroidism, and impaired T-lymphocyte prolifera-
tion.55,58,59 In one adult study comparing dobutamine with
dopamine, both drugs increased myocardial oxygen uptake but
dopamine seemed to cause coronary constriction.53 In children,
an increase in pulmonary artery pressure (PAP) and PVR is
seen with dopamine in a dose higher than 7.5 mg/kg/min.5
Dopamine also causes an increase in cerebral, cardiac, and
intestinal blood flow in term and preterm animals, which is
dose dependent.54 Dopamine has not been proven useful in the
prevention or alteration of the course of acute renal failure.60
When compared to dobutamine, there was no difference in
renal function or urine output in 142 children after heart sur-
gery.6 Again, to our knowledge, there is no literature on the
effect of dopamine on clinically relevant outcomes in children
after heart surgery. However, because of its hemodynamic
effects, it is used to prevent LCOS by 38% of respondents in
this survey.
Other drugs and strategies. Levosimendan, a calcium-sensitizer,
is a relatively new inotrope and one of the most studied.61-64
Levosimendan has a half-life of 1 hour (in adults) and is meta-
bolized into an active metabolite, OR-1896, with a much longer
half-life of 75 to 80 hours.65,66 Both levosimendan and OR-1896
improve myocardial contractility by making troponin C more
sensitive to the available intracellular calcium during systole,
without affecting diastolic function.67 It does not cause chrono-
tropy and does not increase myocardial oxygen demand.68,69 By
stimulating potassium channels in vascular smooth muscle cells,
levosimendan causes peripheral, coronary, and pulmonary vaso-
dilatation.70,71 Because of these effects, levosimendan could be
useful in children with congenital heart disease.72 The most
important side effect is hypotension due to peripheral vasodila-
tion. Levosimendan improves outcomes in adults with acute
decompensation of chronic heart failure, and in adults with poor
left ventricle function undergoing coronary artery bypass sur-
gery.63,64,73 In neonatal and infant congenital cardiac surgery
patients, levosimendan was shown to be as efficacious as milri-
none.15,16 However, myocardial oxygen demand was signifi-
cantly lower in the levosimendan group. In a pediatric study,
levosimendan lowered PAP and increased cardiac index signif-
icantly more than dobutamine.17 But when added to a standard
postoperative protocol of milrinone and dopamine, levosimen-
dan did not improve mortality, duration of MV, or hospital LOS
in one study of 63 neonates.18 After heart surgery, levosimendan
improved peripheral oxygenation (NIRS) and lowered inotrope
scores in 20 children.19 The current level of evidence is insuffi-
cient to judge whether prophylactic levosimendan prevents
LCOS and mortality in pediatric patients undergoing surgery for
congenital heart disease.74 The use of levosimendan is reported
by 5% of respondents of this survey. Currently, there are three
studies registered at clinicaltrials.gov comparing milrinone with
levosimendan in neonatal cardiac surgery (NCT00549107,
NCT01576094, and NCT00695929).
Calciumgluconate is often used based on the knowledge that
the neonatal myocardium is calcium dependent. It increases
MAP and SVR, probably due to peripheral vasoconstriction
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but has been shown not to increase cardiac index in adults or in
premature neonates.75-77 The only report of calciumgluconate
increasing myocardial contractility and cardiac output was in
healthy horses without changing filling pressures or MAP.78
Hypothyroidism, with prolonged ICU LOS, is well
described in adults and children following CPB.23,79-81 Triio-
dothyronin supplementation may be a useful adjunct in the
management of patients after CPB, improving cardiac index,
cardiac function, and inotrope requirements, but its positive
effect on clinical outcomes has not been established.22,23,82,83
New inotropes like istaroxime, nesiritide, apelin, or ome-
camtiv mecarbil have shown some beneficial hemodynamic
effects in adults, but there is too limited evidence in children
at this time.20 Costello et al compared nesiritide with milrinone
and placebo in 106 children following Fontan operation and
found no difference in cardiac index or survival.20 None of the
respondents in this survey reported their use.
Amrinone, a phosphodiesterase inhibitor, is not being used
anymore but has been shown to increase cardiac output in
children following heart surgery.9,13,14
Postoperative Temperature Control
The use of hypothermia during heart surgery is well estab-
lished, decreasing oxygen demand. Following congenital heart
surgery, moderate hypothermia (32C-33C) has been used in
children with refractory low cardiac output state.84 In the retro-
spective study, cooling led to a significant increase in MAP,
pH, and urine output and a decrease in heart rate, right atrial
pressure, and platelet count.
Hyperthermia is known to increase oxygen consumption by
11% for every 1C rise in temperature above 36C.85 There-
fore, it has been advocated that normothermia should be main-
tained in children after cardiac surgery.55 Most respondents of
this survey routinely prevent hyperthermia or try to achieve a
temperature below 37C. Only 9% report to target 35C to
36C degrees routinely after congenital heart surgery with
DHCA. Whether targeting hypothermia will improve outcomes
remains to be investigated. At the moment no clinical trials
comparing postoperative temperature management are regis-
tered at clinicaltrials.gov. The use of hypothermia for heart rate
control is beyond the scope of this survey and review.
Future Research
It would be very interesting to investigate the difference
between milrinone and other inotropes on mortality, duration
of MV, and LOS in future randomized trials These multicenter
trials need to be large enough, which can be a challenge requir-
ing strict study protocols as many other factors may influence
cardiac output postoperatively (eg, anesthesia, surgical tech-
niques, CPB management and duration, postoperative sedation,
extubation management, fluid management, and ICU treatment
goals such as temperature, pH, blood pressure, etc). Further-
more, these studies have to focus on specific congenital defects
as different disease states (eg, biventricular vs univentricular
heart disease, VSD vs Fallot, Norwood versus Fontan, etc) will
require different inotrope approaches. But first we may have to
focus on the pharmacokinetic aspect of inotropes, assessing the
effect of inotropic plasma levels on cardiac output and then try
to find a dose–effect relationship. This will also need to be done
in different age-groups. It will be very hard to convincingly
show benefit of one inotrope over another in the many specific
situations intensivists are faced with.
Currently three studies are comparing levosimendan and
milrinone, hopefully these studies will be large enough to focus
on the important clinical outcomes and not only the hemody-
namic effects.
Limitations
The survey results are limited by the reliance on the self-reports
by the participants. One limitation of the survey was that it did
not specifically address the dosage of the different drugs that
are being been used nor did we address the different types of
LCOS. Another limitation is that the survey was set up to
determine provider-dependent practice variation rather than
center-dependent variation and it was therefore also not possi-
ble to compare practice variation between the different conti-
nents and/or countries. However, the average number of
respondents per center is approximately 1.6, which is consis-
tent for all centers apart from the European and South African
centers which both had one respondent per center. Therefore,
the practice variation we identified in all respondents also
reflects practice variation in the different centers and probably
indicates that practice variation is more center dependent than
provider dependent.
Conclusions
There are several inotropes available to the (cardiac) intensivist
with, more or less, well described hemodynamic effects. The
use of these inotropes seems very logical and appropriate in the
prevention and treatment of low cardiac output states following
pediatric heart surgery. Different inotropes can be used for
different clinical situations, but the choice of inotrope is up
to the treating physician as there is a lack of compelling evi-
dence in the literature favoring one inotrope over another or
even placebo. Despite this currently insufficient evidence on
clinically relevant outcomes, milrinone is, by far, most often
used for the treatment and prevention of low cardiac output in
children worldwide.
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